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Abstract: Engineered multivalent drugs are promising candidates for fighting infection by highly
variable viruses, such as HCV. The combination into a single molecule of more than one inhibitory
domain, each with its own target specificity and even a different mechanism of action, results in
drugs with potentially enhanced therapeutic properties. In the present work, the anti-HCV chimeric
inhibitor RNA HH363-10, which has a hammerhead catalytic domain and an aptamer RNA domain,
was subjected to an in vitro selection strategy to isolate ten different optimised chimeric inhibitor
RNAs. The catalytic domain was preserved while the aptamer RNA domain was evolved to contain
two binding sites, one mapping to the highly conserved IIIf domain of the HCV genome’s internal
ribosome entry site (IRES), and the other either to IRES domain IV (which contains the translation start
codon) or the essential linker region between domains I and II. These chimeric molecules efficiently
and specifically interfered with HCV IRES-dependent translation in vitro (with IC50 values in the low
µM range). They also inhibited both viral translation and replication in cell culture. These findings
highlight the feasibility of using in vitro selection strategies for obtaining improved RNA molecules
with potential clinical applications.
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1. Introduction
The ability to interfere at the genetic level with the functioning of RNA viruses has long
been an area of interest. One of the most promising lines of research in this respect has involved
the development of nucleic acid-based inhibitory molecules. Therapeutic nucleic acids have advantages
over other targeted drugs such as those based on antibodies; for example, they show low immunogenicity
and their production is easier, minimizing structural variations among different batches. However,
their low biostability, a consequence of their rapid renal filtration and degradation by nucleases, is a
problem. Fortunately they can be modified to avoid these drawbacks, for example by adding groups
that improve either their uptake by cells, their binding affinity, or their stability against nucleases [1].
The use of aptamers as therapeutic and diagnostic agents has become a feasible option. Aptamers
are single-stranded DNA or RNA molecules that bind in a very specific and efficient manner to
their targets. Aptamers are isolated by an in vitro selection procedure known as SELEX (systematic
evolution of ligands by exponential enrichment) [2,3]. From a highly heterogeneous initial population,
usually composed of 1012 to 1015 variants, consecutive selection rounds identify aptamers against
specific targets. The fact that the aptamer action can be reversed by an antidote has drawn them much
clinical interest [4–6].
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Strong target affinity is critical in the development of an efficient aptamer. Numerous authors ([7,8]
and references therein) report this to have been achieved using the SELEX process by modifying the
temperature or ionic conditions. The incorporation of chemical modifications, either during the in vitro
selection procedure or as post-SELEX editing process, also allows the optimization of the aptamers
available [9–12]. The incorporation of further anchoring sites, yielding multivalent molecules, can also
increase the affinity of monovalent compounds [13–17]. A conventional way of designing multivalent
aptamers is to connect independent modules. The main drawback of this strategy is the need to
preserve aptamer folding. In addition, the concatenation of multiple monomers produces long
molecules that are hard to synthesize and deliver into cells.
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red. Residues proposed to interact with the aptamer domain of HH-11 and HH-17 are shown in blue. 
The theoretical anchoring site for HH-26 is indicated in blue and underlined. Nucleotides pictured in 
green, located in the linker region between domains I and II, likely act as a binding region for the 
aptamer domain of the chimeric inhibitors HH-13, HH-22, HH-24, HH-28 and HH-43; (B) Sequence 
and theoretical secondary structure model of HH363-10. Figure was adapted from [14]. The catalytic 
domain, HH363, is shadowed. Tertiary contacts are indicated by dotted lines. Residues in the 
aptamer domain responsible for the interaction with domain IIIf of the IRES are shown in red. 
Randomization of the residues flanking this sequence motif, plus partial mutagenesis of those 
nucleotides participating in the IIIf binding site, yielded an initial population of more than 6 × 107 
theoretical variants (lower panel). R, G or A; K, G or U; PK, pseudoknot. 
Our group previously isolated the RNA inhibitor HH363-10 using an innovative in vitro selection 
strategy [13,14]. This method uses two sequential steps of selection for two distinct activities, binding 
Figure 1. The HCV IRES region and the parental HH363-10 chimeric inhibitor employed as the
prototype for the construction of the RNA pool. (A) Sequence and secondary structure of the HCV IRES
including the functional RNA domains targeted by the selected chimeric inhibitory RNA molecules.
The IRES site cleaved by HH363-10 is indicated by an arrow. The translation start codon at position
342 is enlarged. The nucleotides that interact with the aptamer domain of HH363-10 are shown in
red. Residues proposed to interact with the aptamer domain of HH-11 and HH-17 are shown in blue.
The theoretical anchoring site for HH-26 is indicated in blue and underlined. Nucleotides pictured
in green, located in the linker region between domains I and II, likely act as a binding region for the
aptamer d main of the chimeric inhibitors H -1 , HH-22, HH-24, HH-28 and HH-43; (B) Sequence
and theoretical secondary structure model of HH363-10. F gure was adapted from [14]. The catalytic
domain, HH363, is shadowed. Tertiary contacts are indicated by dotted lines. Residues in the aptamer
domai responsible for the interaction with domain IIIf of the IRES are shown in red. Rand mization of
the residues flanking this sequence motif, plus partial mutagenesis of those nucleotides participating in
the IIIf binding site, yielded an initial population of more than 6× 107 theoretical variants (lower panel).
R, G or A; K, G or U; PK, pseudoknot.
Our group previously isolated the RNA inhibitor HH363-10 using an innovative in vitro selection
strategy [13,14]. This method uses two sequential steps of selection for two distinct activities, binding to
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the HCV IRES region and cleavage at nucleotide 363 of the genomic viral RNA. This procedure yielded
chimeric RNA molecules composed of two inhibitory RNA domains, an aptamer and a catalytic domain.
HH363-10 can bind to the highly conserved IIIf domain of the essential internal ribosome entry site
(IRES) in the HCV genome through the aptamer domain (Figure 1) [13,14]. Domain IIIf is a key element
in the three-dimensional organization of the IRES, and participates extensively in the recruitment and
assembly of the 40S ribosomal particle [18,19]. It therefore appears as an interesting candidate target
for the development of new antiviral molecules. HH363-10 also harbours a hammerhead ribozyme
domain that cleaves (though at low efficiency) the viral RNA at a position spatially close to the IIIf
aptamer-targeting site (Figure 1A). This design provided a potent inhibitory RNA able to interfere
with HCV translation in cell culture [14]—a prototype molecule for further improvement.
The present work reports the isolation of novel chimeric inhibitory RNA molecules based on
HH363-10. These bear the parental anchoring site for the domain IIIf in the aptamer component, but
also possess a secondary anchoring site that does not interfere with the catalytic properties of the
hammerhead component. The resulting molecules efficiently interfered with HCV IRES-dependent
translation in vitro and in a human-derived hepatoma cell line. Further, they strongly inhibited viral
RNA synthesis, confirming the potential of multivalent RNA molecules as therapeutic agents for use
against HCV.
2. Results
2.1. Isolation of Improved RNA Molecules that Interfere with HCV IRES Function In Vitro
The chimeric inhibitor HH363-10 was subjected to the previously described in vitro selection
procedure [13,14], with the aim of identifying inhibitory RNA molecules that act against the IRES
region of the HCV genome, and that showed improved aptamer and catalytic properties. For this,
an RNA pool was designed (Figure 1B), based on the HH363-10 inhibitor, adhering to the following
criteria: (i) the maintenance of the sequence motif responsible for the aptamer’s interaction with
the domain IIIf of the IRES; (ii) randomization of the nucleotides flanking the interacting sequence
with the aim of isolating RNA molecules bearing secondary anchoring sites at the HCV IRES region
besides the primary domain IIIf. This RNA pool was then subjected to in vitro selection as previously
described [13]. After seven selection rounds, 10 RNA variants (HH-11, HH-13, HH-15, HH-17, HH-22,
HH-24, HH-26, HH-28, HH-33 and HH-43; Figure 2) were isolated and analysed for their ability to
inhibit IRES-dependent translation in vitro. Sequence analysis using the RNAup software tool [20]
showed new theoretical interaction sites to map to the conserved domain IV, and to the interdomain
I-II regions (Figure 1A). This showed the selection strategy to have worked properly.
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Figure 2. Sel cted RNA molecules targ ti r ion. Sequences of the 10 s lected
chimeric inhib tory RNAs after seven roun s f . Residues in grey denote the conserved
catalytic domain of the inhibitory RNA. The sequence motif involved in the interaction with the domain
IIIf is indicated in red. The nucleotides theoretically targeting domain IV and the linker sequence
between domains I and II within the IRES are pictured in blue and green respectively. The unique
sequence in HH-26 that binds to the apical loop of IRES domain IV is also underlined.
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The activity of the different chimeric inhibitors was examined in in vitro translation assays
involving two monocistronic RNA molecules (used as templates) in rabbit reticulocyte lysates [14]. One
of these monocistronic RNAs, IRES-FLuc, encompasses the HCV IRES region directing the synthesis of
the reporter FLuc protein; the other, cap-RLuc, codes for the RLuc enzyme (which is translated in a
cap-dependent manner). Each inhibitor was assayed at a concentration of 5 µM. HH-11, HH-13, HH-26,
HH-28 and HH-43 efficiently interfered with IRES function (Figure 3), showing inhibition values close
to 97%. HH-15, HH-17, HH-22, HH-24 and HH-33 also promoted a reduction in FLuc synthesis, but to
a lesser extent (20–60%). Cap-dependent translation was not affected (<5%, data not shown) for any of
the assayed chimeric inhibitory RNAs at the concentration tested, demonstrating the specific nature of
the inhibition of IRES function.
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Figure 3. Specific inhibition of HCV IRES-dependent translation in vitro by the selected chimeric
inhibitory RNAs. (A) The bar chart shows the relative synthesis of FLuc protein directed by the HCV
IRES region achieved in the presence of 5 µM of each chimeric inhibitory RNA, normalized to that
obtained for the cap-dependent translation of cap-RLuc mRNA. The resulting values were referred to
the results obtained in the absence of inhibitory RNA. Data are the mean of at least three independent
assays ± standard deviation represented by the error bars; (B) The plot shows the relative reduction in
FLuc synthesis caused by the chimeric inhibitors HH-11, HH-13, HH-26, HH-28 and HH-43. Data were
normalized to those obtained for the synthesis of the RLuc reporter protein. The relative amount of
FLuc obtained at each inhibitor concentration is calculated as a percentage with respect to the control
reaction in the absence of any chimeric inhibitory RNA. Data (the mean of three independent assays ±
stan ard deviation) were fitted to a non-linear regression curve to determine the IC50 values; (C) The
histogram shows the effec of each anti-HCV inhibitory RNA on the IRES function of the closely related
GBV-B virus. The synthesis of the FLuc protein was normalized as noted in A). Data are he mean of
three independent assays ± standard deviation.
The potential of the five most efficient chimeric inhibitor RNAs—HH-11, HH-13, HH-26, HH-28
and HH-43—as IRES interfering agents was then further characterised using different concentrations
of each, ranging from an IRES-FLuc:inhibitor RNA molar ratio of 1:1 to 8:1. Potent dose-dependent
inhibition was recorded for HH-11, with an IC50 value of 170 ± 20 nM and a maximum inhibition
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of close to 100% (Table 1; Figure 3B). These results are better than those reported with the parental
chimeric inhibitor HH363-10 [14], which showed a maximum inhibition of 90%. More importantly,
maximum inhibition with HH-11 was attained at 1 µM, whereas HH363-10 required a concentration of
2.5 µM to achieve the 90% inhibition. Inhibitor RNAs HH-13, HH-26, HH-28 and HH-43 also affected
the function of the HCV IRES in a dose-dependent manner, with IC50 values in the low µM range and
maximum inhibition values of 90–95% (Table 1; Figure 3B).
Table 1. IC50 values of the different inhibitory RNAs.
Inhibitor IC50 (µM) a Relative Fluc Synthesis (%) b
HH363-10 [14] 0.15 ± 0.04 11.22 ± 2.77
HH-11 0.17 ± 0.02 0.01 ± 1.10
HH-13 0.91 ± 0.31 8.78 ± 2.21
HH-26 1.46 ± 0.24 9.25 ± 1.47
HH-28 0.44 ± 0.06 2.56 ± 1.34
HH-43 1.02 ± 0.15 1.00 ± 0.40
a IC50 values were derived from the equation y = 100/(1 + 10(LogIC50−X)); b Data correspond to the highest
concentration of inhibitor tested. Values are the mean of three independent assays ± standard deviation.
To further investigate the specificity of the inhibitors against the HCV IRES region, in vitro
translation assays were performed with the construct IRESGBV-B -FLuc, which bears the IRES region
of the closely related hepacivirus GBV-B [21] fused to the coding sequence for the FLuc protein [15].
Interestingly, only the chimeric inhibitor HH-11 significantly affected GBV-B IRES activity (Figure 3C),
while the rest of the tested inhibitory RNAs showed marked specificity for the HCV IRES region.
The notable conservation of the 5’UTR among hepacivirus suggests that HH-11 might target a common
key structural motif, thus resulting in the inhibition of GBV-B IRES activity. Other sequence motifs in
the aptamer domain might also target the GBV-B IRES. Finally, it should be noted that although HH-11
interfered with GBV-B IRES-dependent translation, it did not affect cap-mediated RLuc synthesis
(data not shown). This shows that HH-11 is not a generic translation inhibitor, but rather that it is
specific for sequence and/or structural motifs in the hepacivirus IRES.
Taken together, these results show that the isolated chimeric inhibitor RNAs operate as improved
inhibitors of HCV IRES function compared to the prototype HH363-10.
2.2. The Chimeric Inhibitor RNAs Inhibit HCV IRES-Dependent Translation in Cell Culture
The effect of the HH-11, HH-13, HH-26, HH-28 and HH-43 chimeric inhibitors on HCV
IRES-dependent translation was also evaluated in cell culture. Human hepatoma cell line Huh-7
was co-transfected with a mixture containing the RNA constructs IRES-FLuc and cap-RLuc and a
molar excess of an inhibitory RNA (25:1). The resulting data were compared with those obtained
in the presence of a non-related RNA molecule, RNA80 [14,16], used to complement the total RNA
amount in the transfection mix. The five tested molecules provoked a significant reduction (60–80%) in
HCV-IRES activity (Figure 4A). HH-11 appeared as a potent inhibitory RNA, in good agreement with
the results of the in vitro translation assays (Figure 3A). HH-26 and HH-28 also induced significant
reductions (nearly 80%) in IRES activity, showing them to be improved anti-HCV agents.
2.3. Interference with HCV Replication by the Chimeric Inhibitors
The effect of HH-11, HH-13, HH-26, HH-28 and HH-43 on HCV replication was also investigated.
Huh-7 cells bearing a subgenomic replicative RNA molecule derived from HCV (Huh-7 NS3-3’; [22,23])
were transiently transfected with 175 nM of inhibitory RNA or the non-related RNA80 molecule.
The amount of replicative HCV RNA was determined 24 h post-transfection by RT-qPCR, and
normalized to that of the intracellular mRNA encoding for GAPDH protein (see Materials and
Methods). The selected chimeric inhibitors significantly interfered with HCV replication (Figure 4B),
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promoting a 60–80% reduction in viral RNA positive strands with respect to the control assay.
Interestingly, these data contrast with those obtained for HH363-10 (Figure 4B), which affected HCV
replication much more weakly (~25% reduction in HCV RNA levels). This result confirms the improved
inhibitory ability of the selected chimeric inhibitor RNAs over the parental HH363-10.
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a human hepatoma cell line. (A) Huh-7 cells were transfected with 5 µg of each chimeric inhibitory
RNA or the non-related RNA80, plus 1.1 µg of a mixture containing the IRES-FLuc mRNA and
the cap-RLuc. Luciferase activity was measured 18 h after transfection and the values turned into
percentages by refere ce to the results obt ine in the control assay with RNA80. Data are the mean
of four indep dent experiments ± standard devia ion represented by the error bars; (B) Five µg of
the different chimeric inhibitory RNAs were used to tra sfect Huh-7 cells stably supporting HCV
replication. Total RNA was extracted 24 h post-transfection using TRIzol™, and the relative amount of
HCV RNA quantified by RT-qPCR. Data are the mean of four independent assays± standard deviation
represented by the error bars.
3. Discussion
The development of novel diagnostic and therapeutic tools for dealing with viral infections is a
major cientific goal. In recent y ars, aptamers have become candidates as therapeutic alternatives to
monoclonal antibodies, which are highly immunogenic and expensi o produce. Apta e can also
be optimized to provide even more efficient inhibitors, as long as their three dimensional structure is
preserved. Many strategies are now available to improve the affinity of aptamers for their targets, to
increase their resistance to nucleases, and to improve their delivery to cells ([24] and references therein).
Conventional monovalent aptamers have short retention times at their targets, reducing their
therapeutic indices, but multivalent aptamers, bearing at least two different targeting sites, demonstrate
improved affinity [25]. Multivalent aptamers are usually produced by the consecutive joining of
monovalent monomers, either directly or via linkers. The main drawback here is that the structure of
the aptamer can be altered, whic can reduce its clinic l effectiveness. In ad ition, the i crease in the
aptamer length r sults in a m re expens ve and less efficient production. Customized in vitro selection
strategies, however, allow new targeting sites to be added to an inhibitory molecule’s repertoire
without disturbing its conformation.
The chimeric RNA molecule HH363-10 has both catalytic and aptamer properties, and targets
two sites in the HCV IRES region [14]. In cell culture, it can reduce viral translation by ~50%. In the
present work, in vitro selection was used to further improve its inhibitory properties. Ten variants
were isolated, all of which were able to interfere with HCV IRES function (Figures 2 and 3). HH-11,
HH-13, HH-26, HH-28 and HH-43 induced a strong reduction in viral translation both in vitro and in
cell culture, with IC50 values in the low µM rang achiev d (Figure 3B), and in ibition values up to
almost 100% obtained (Figure 3B). The properties of the paren al compound HH363-10 were therefore
improved [14].
RNAup [20] and RNAstructure [26] software have been used in in silico searches for target sites
within the IRES beyond the original anchoring region for the aptamer in the domain IIIf. The presence
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of additional anchoring sites in the chimeric inhibitor RNAs might explain the improvement in the
inhibitory capacity of the novel selected chimeric ones (Figure 5). The present analyses revealed HH-11
and HH-26 to have acquired an additional anchoring region with a target in the 3’ flank and the apical
loop of IRES domain IV respectively (Figures 1, 2 and 5). Domain IV is close to the primary target
site in domain IIIf, suggesting that a single inhibitor RNA might bind to both. However, it cannot be
ruled out that two different molecules of the same inhibitor use their different anchoring sites in a
shared attack on different IRES sites. The identified sequence motifs of 5′-GUGUG-3′ for HH-11, and
5′-CUCAU-3′ for HH-26, consist of five residues upstream of the parental anchoring sequence (which
has 9 nt) (Figures 1, 2 and 5). It is tempting to speculate that the first interaction between inhibitor
and target is directed by the longer primary motif targeting the domain IIIf, with the second site then
helping to stabilize the resulting complex. It is interesting that intact domain IV conformation and
stability are required for efficient IRES-dependent translation [27]. This might help explain the potent
inhibitory activity of the chimeric inhibitor RNAs HH-11 and HH-26, which target this domain.
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The molecules HH-13, HH-28 and HH-43 were predicted to bear a sequence motif in their aptamer
domain, 5′-UGGUG-3′, able to interact with the linker region between domains I and II (Figures 1, 2
and 5). This contact can be used as a secondary anchorage after the initial interaction with domain
IIIf. The linker sequence in the IRES might locate spatially close to the pseudoknot structure by virtue
of a long range RNA-RNA interaction with domain VI [28], which fits well with the hypothesis that
both anchoring sites could be used by a single, multivalent compound. It has also been demonstrated
that this region is the target of the essential microRNA miR-122. This interaction promotes both viral
translation and replication [29–31]. This agrees well with the extensive inhibitory effect promoted by
the chimeric inhibitory RNAs.
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It should be noted that HH-17 shares the second interacting sequence, 5′-GUGUG-3′, with
HH-11, while HH-22 and HH-24 acquired the sequence motif 5′-UGGUG-3′, which is present in the
chimeric inhibitors HH-13, HH-28 and HH-43 (Figures 1 and 2). Interestingly, they only showed slight
inhibitory activity, suggesting that factors beyond the incorporation of new anchoring sequence motifs
are involved in anti-HCV activity, e.g., the aptamer structure.
In conclusion, the present work shows that in vitro selection allows chimeric inhibitory RNAs
to be obtained that target three different sites in the HCV genome. These inhibitors might be further
optimized by the introduction of nucleotide analogues and/or chemically modified nucleotides to
provide efficient antiviral drugs. This strategy should be extended to other viral diseases in order to
develop further sets of molecules with potent therapeutic properties.
4. Materials and Methods
4.1. Cell Lines and Culture Conditions
Cell monolayers of the human hepatoma cell line Huh-7 were maintained in Dulbecco’s
modified Eagle medium (DMEM) supplemented with 10% heat-inactivated foetal bovine serum
(FBS; Invitrogen™, Waltham, MA, USA) and 1 mM sodium pyruvate (Sigma, St. Louis, MO, USA), at
37 ◦C in a 5% CO2 atmosphere.
Huh-7-NS3-3′ cells supporting an HCV subgenomic replicon (genotype 1b) were grown in DMEM
supplemented with 20% heat-inactivated FBS, 1 mM sodium pyruvate (Sigma) and 0.5 mg/mL G-418.
The subgenomic replicon construct consists of the HCV-IRES (genotype 1b), followed by the neomycin
phosphotransferase gene, the IRES region of the encephalomyocarditis virus (EMCV), the coding
sequence for non-structural HCV proteins (NS3–NS5), and the HCV 3’UTR.
4.2. DNA Templates and RNA Synthesis
DNA templates encoding the chimeric inhibitors HH363-10, HH-11, HH-13, HH-15, HH-17,
HH-24, HH-26, HH-28, HH-33 and HH-43 were obtained by PCR as previously described [13].
The coding sequence for GB virus B (GBV-B), IRESGBV-B-FLuc, was obtained by PCR amplification as
previously reported [16]. The RNA constructs IRES-FLuc, cap-RLuc and RNA80 were synthesized as
previously described [14,16].
RNA molecules were obtained by in vitro transcription using the RiboMAX™-T7 large-scale RNA
production system (Promega, Madison, WI, USA) following the manufacturer’s instructions. During
the synthesis of cap-RLuc, a cap structure was incorporated into its 5’ end by adding 2 mM of Ribo
m7G Cap analog (Promega). The resulting RNAs were purified by phenol/chloroform extraction and
size exclusion chromatography (Sephadex G-25; GE Healthcare, Little Chanfont, UK). The amount and
quality of the resulting RNA samples were determined by A260 and A280 measurements, followed by
agarose-formaldehyde gel electrophoresis.
4.3. In Vitro Translation Assays
IRES-FLuc and cap-RLuc mRNAs were in vitro translated using the Flexi® rabbit reticulocyte
lysate system (Promega). Reactions proceeded in 6 µL volumes containing 4 µL cell extract, 1 mM of
an amino acid mixture lacking methionine, 100 mM KCl and 1.5 µCi of a mixture of L-[35S]methionine
and L-[35S]cysteine (all from the Redivue Pro-mix L-[35S] in vitro cell labelling mix; GE Healthcare).
The RNA templates for the synthesis of FLuc (HCV IRES-FLuc or IRESGBV-B -FLuc) and RLuc
(cap-RLuc) proteins were added to a final concentration of 30 ng/µL (~40 nM) and 20 ng/µL (~60 nM)
respectively. Inhibitory RNA concentrations ranging from 40 nM to 5 µM were assayed. Prior to their
incorporation into the translation mix, all the RNA molecules were denatured by heating at 95 ◦C for
2 min and cooling at 4 ◦C for 15 min. Translation proceeded at 30 ◦C for 60 min. Reactions were stopped
by cooling on ice and the protein products resolved on 12.5% (w/v) denaturing polyacrylamide gels.
Dried gels were scanned in a Phosphorimager (Storm 820, GE Healthcare) and quantified using Image
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Quant 5.2® software (GE Healthcare). The IC50 values were calculated using SigmaPlot 8.02® software
(Systat Software Inc., San José, CA, USA) from the equation
y = ymax/(1 + 10(LogIC50−X))
where ymax is the maximum percentage of FLuc relative synthesis, IC50 the inhibitor concentration
that produces 50% of the maximum observed effect, and X the inhibitor concentration.
4.4. RNA Transfection
The cell lines Huh-7 and Huh-7 NS3-3′ were transfected as previously reported [14,15]. To assess
the inhibitory activity of the chimeric RNA molecules ex vivo on HCV IRES-dependent translation,
Huh-7 cells were used as model system. 90,000 cells/well were seeded onto a 24-well plate and
allowed to reach 80–90% confluence (36–48 h). A mix containing 1 µg of the RNA construct IRES-FLuc
and 100 ng of cap-RLuc was supplemented with 5 µg of each chimeric inhibitor or the non-related
RNA80. TransFectin™ (Bio-Rad, Hercules, CA, USA) was used as the transfection reagent following
the manufacturer’s instructions. Luciferase activity was detected 18 h after transfection using the
Dual-Luciferase™ reporter assay system (Promega).
Analysis of the inhibitory effect on HCV replication was performed by transfecting Huh-7-NS3-3′
cells with the different chimeric inhibitors under study. At 24 h before transfection, 90,000 cells were
seeded and grown until 80% confluence in 1.5 cm diameter dishes in the presence of culture medium
without G-418. The cells were then transfected with 4 µg of each inhibitor RNA or RNA80 using
TransFectin™ (Bio-Rad). At 24 h post-transfection, the cells were harvested and processed for further
RNA extraction.
4.5. Relative Quantification of HCV Subgenomic RNA
Intracellular HCV replicon positive-strand RNA levels were measured as previously
described [32]. Briefly, total RNA was extracted using TRIzol™ (Invitrogen™ via Thermo Fisher
Scientific, Carlsbad, CA, USA) following the manufacturer’s instructions. 50 ng of the purified RNA
were then reverse transcribed using the High-Capacity cDNA Reverse Transcription Kit (Applied
Biosystems via Thermo Fisher Scientific) and 1 µg of random primers. A fraction of the cDNA
product was used for quantitative PCR using the SsoFast™ Evagreen® Supermix Kit (Bio-Rad) and
amplified over 40 cycles using specific oligonucleotides targeting the IRES region (C-149 and C-342) [33].
In parallel, RT-qPCR of the mRNA encoding the human glyceraldehyde-3-phosphate dehydrogenase
(hGAPDH) was performed using the primers hGAPDH_Fw and hGAPDH_Rev [34]. The resulting data
were used to calculate the relative amount of HCV subgenomic RNA. Reactions were performed using
the Bio-Rad CFX 96 real time system, and data analyzed using Bio-Rad CFX real time manager software.
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